Published by Benjamin Chiou on 8th October 2024
(Sharecast News) - GSK has announced positive results from a phase III trial of its Arexvy RSV vaccine, showing that just one dose of the treatment could help protect older adults at risk of RSV disease over three seasons.
URL: http://www.digitallook.com/dl/news/story/34609578/...